CompletedN/Aketamine
Ondansetron Reduce Vomiting Associated With Ketamine PSA
Sponsored by University of Colorado, Denver
NCT ID
NCT00387556
Target Enrollment
268 participants
Start Date
2002-12
Est. Completion
2006-12
About This Study
Ondansetron, a commonly used anti-vomiting medication, may reduce the occurrence of vomiting associated with ketamine during procedural sedation in the pediatric emergency department.
Conditions Studied
Interventions
- •Ondansetron
Eligibility
Age:1 Year - 21 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * age 1-21 years, ASA I or II, fracture of dislocation reduction Exclusion Criteria: * age \< 1 year, ASA III or IV, hypertension, glaucoma, acute globe injury, increased intracranial pressure or central nervous system mass lesion, major psychiatric disorder, porphyria, previous adverse reaction to ketamine or ondansetron, parent, guardian or patient unwilling to provide informed consent.
Study Locations (1)
The Childrens Hospital
Denver, Colorado, United States